GB201423361D0 - Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides - Google Patents

Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides

Info

Publication number
GB201423361D0
GB201423361D0 GBGB1423361.3A GB201423361A GB201423361D0 GB 201423361 D0 GB201423361 D0 GB 201423361D0 GB 201423361 A GB201423361 A GB 201423361A GB 201423361 D0 GB201423361 D0 GB 201423361D0
Authority
GB
United Kingdom
Prior art keywords
absolute quantification
naturally processed
cancer peptides
restricted cancer
processed hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1423361.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Priority to GBGB1423361.3A priority Critical patent/GB201423361D0/en
Publication of GB201423361D0 publication Critical patent/GB201423361D0/en
Priority to PL15822924T priority patent/PL3241026T3/pl
Priority to EA201791148A priority patent/EA036328B1/ru
Priority to MYPI2017700825A priority patent/MY190199A/en
Priority to PE2017000941A priority patent/PE20171136A1/es
Priority to US14/969,423 priority patent/US10545154B2/en
Priority to KR1020177017911A priority patent/KR102336968B1/ko
Priority to PCT/EP2015/079873 priority patent/WO2016107740A1/en
Priority to SG11201703841VA priority patent/SG11201703841VA/en
Priority to HRP20210811TT priority patent/HRP20210811T1/hr
Priority to JP2017521534A priority patent/JP6735741B2/ja
Priority to MA41287A priority patent/MA41287B1/fr
Priority to SI201531612T priority patent/SI3241026T1/sl
Priority to EP15822924.5A priority patent/EP3241026B1/en
Priority to PT158229245T priority patent/PT3241026T/pt
Priority to AU2015373584A priority patent/AU2015373584B2/en
Priority to DK15822924.5T priority patent/DK3241026T3/da
Priority to HUE15822924A priority patent/HUE054455T2/hu
Priority to MX2017008722A priority patent/MX383806B/es
Priority to ES15822924T priority patent/ES2871035T3/es
Priority to BR112017008212-8A priority patent/BR112017008212B1/pt
Priority to UAA201701977A priority patent/UA122774C2/uk
Priority to CN201580063711.6A priority patent/CN107003322B/zh
Priority to CR20170297A priority patent/CR20170297A/es
Priority to MDE20170252T priority patent/MD3241026T2/ro
Priority to TW104142137A priority patent/TWI632370B/zh
Priority to MA40137A priority patent/MA40137B1/fr
Priority to RS20210672A priority patent/RS61914B1/sr
Priority to LTEP15822924.5T priority patent/LT3241026T/lt
Priority to SG10201913988XA priority patent/SG10201913988XA/en
Priority to CA2972306A priority patent/CA2972306C/en
Priority to ZA2017/01646A priority patent/ZA201701646B/en
Priority to IL250982A priority patent/IL250982B/en
Priority to PH12017500483A priority patent/PH12017500483A1/en
Priority to CL2017001071A priority patent/CL2017001071A1/es
Priority to CONC2017/0004543A priority patent/CO2017004543A2/es
Priority to US16/685,765 priority patent/US11988669B2/en
Priority to CY20211100514T priority patent/CY1124223T1/el
Priority to US18/638,970 priority patent/US20240280583A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
GBGB1423361.3A 2014-12-30 2014-12-30 Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides Ceased GB201423361D0 (en)

Priority Applications (39)

Application Number Priority Date Filing Date Title
GBGB1423361.3A GB201423361D0 (en) 2014-12-30 2014-12-30 Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
CA2972306A CA2972306C (en) 2014-12-30 2015-12-15 Method for the absolute quantification of naturally processed hla-restricted cancer peptides
MX2017008722A MX383806B (es) 2014-12-30 2015-12-15 Metodo para la cuantificacion absoluta de peptidos cancerosos restringidos a hla que son procesados de forma natural.
ES15822924T ES2871035T3 (es) 2014-12-30 2015-12-15 Método para la cuantificación absoluta de péptidos cancerosos restringidos a HLA que son procesados de forma natural
MYPI2017700825A MY190199A (en) 2014-12-30 2015-12-15 Method for the absolute quantification of naturally processed hla-restricted cancer peptides
PE2017000941A PE20171136A1 (es) 2014-12-30 2015-12-15 Metodo para la cuantificacion absoluta de peptidos cancerosos restringidos a hla que son procesados de forma natural
US14/969,423 US10545154B2 (en) 2014-12-30 2015-12-15 Method for the absolute quantification of naturally processed HLA-restricted cancer peptides
KR1020177017911A KR102336968B1 (ko) 2014-12-30 2015-12-15 자연적으로 처리된 hla-제한 암 펩티드의 절대 정량 방법
PCT/EP2015/079873 WO2016107740A1 (en) 2014-12-30 2015-12-15 Method for the absolute quantification of naturally processed hla-restricted cancer peptides
SG11201703841VA SG11201703841VA (en) 2014-12-30 2015-12-15 Method for the absolute quantification of naturally processed hla-restricted cancer peptides
HRP20210811TT HRP20210811T1 (hr) 2014-12-30 2015-12-15 Metoda apsolutne kvantifikacije prirodno prerađenih peptida raka ograničenih na hla
JP2017521534A JP6735741B2 (ja) 2014-12-30 2015-12-15 自然にプロセスされたｈｌａ拘束性がんペプチドを絶対的定量化する方法
MA41287A MA41287B1 (fr) 2014-12-30 2015-12-15 Procédé permettant la quantification absolue des peptides contre le cancer restreints aux molécules hla traités naturellement
SI201531612T SI3241026T1 (sl) 2014-12-30 2015-12-15 Postopek absolutne kvantifikacije naravno obdelanih peptidov raka, omejenih s HLA
EP15822924.5A EP3241026B1 (en) 2014-12-30 2015-12-15 Method for the absolute quantification of naturally processed hla-restricted cancer peptides
PT158229245T PT3241026T (pt) 2014-12-30 2015-12-15 Método para quantificação absoluta de péptidos cancerosos naturalmente processados e restritos por hla
AU2015373584A AU2015373584B2 (en) 2014-12-30 2015-12-15 Method for the absolute quantification of naturally processed hla-restricted cancer peptides
DK15822924.5T DK3241026T3 (da) 2014-12-30 2015-12-15 Fremgangsmåde til absolut kvantificering af naturligt forarbejdede hla-begrænsede cancerpeptider
EA201791148A EA036328B1 (ru) 2014-12-30 2015-12-15 Способ определения абсолютных количеств hla-рестриктированных раковых пептидов, образовавшихся в результате естественного процессинга
PL15822924T PL3241026T3 (pl) 2014-12-30 2015-12-15 Metoda bezwzględnego określenia ilościowego naturalnie przetwarzanych ograniczonych do hla peptydów nowotworowych
BR112017008212-8A BR112017008212B1 (pt) 2014-12-30 2015-12-15 Método de quantificação absoluta de pelo menos um peptídeo ligante de mhc em uma célula
HUE15822924A HUE054455T2 (hu) 2014-12-30 2015-12-15 Módszer a természetes módon feldolgozott, HLA-korlátozott rákpeptidek abszolút mennyiségi meghatározására
MDE20170252T MD3241026T2 (ro) 2014-12-30 2015-12-15 Metodă pentru cuantificarea absolută a peptidelor de cancer restricționate de HLA procesate natural
CN201580063711.6A CN107003322B (zh) 2014-12-30 2015-12-15 天然加工的hla限制性癌肽绝对定量方法
CR20170297A CR20170297A (es) 2014-12-30 2015-12-15 Método para la cuantificación absoluta de péptidos cancerosos restringidos a hla que son procesados de forma natural
UAA201701977A UA122774C2 (uk) 2014-12-30 2015-12-15 Спосіб визначення абсолютних кількостей hla-рестриктованих ракових пептидів, що утворюються в результаті природного процесингу
TW104142137A TWI632370B (zh) 2014-12-30 2015-12-15 天然加工的ｈｌａ限制性癌胜肽絕對定量方法
MA40137A MA40137B1 (fr) 2014-12-30 2015-12-15 Procédé permettant la quantification absolue des peptides contre le cancer restreints aux molécules hla traités naturellement
RS20210672A RS61914B1 (sr) 2014-12-30 2015-12-15 Metod za apsolutnu kvantifikaciju prirodno obrađenih hla- restrikovanih peptida malignih tumora
LTEP15822924.5T LT3241026T (lt) 2014-12-30 2015-12-15 Natūraliai apdorotų vėžio peptidų su pašalintais hla aleliais absoliučiojo kiekio nustatymo metodas
SG10201913988XA SG10201913988XA (en) 2014-12-30 2015-12-15 Method for the absolute quantification of naturally processed hla-restricted cancer peptides
IL250982A IL250982B (en) 2014-12-30 2017-03-07 An absolute method for the quantification of restricted, naturally processed cancer peptides
ZA2017/01646A ZA201701646B (en) 2014-12-30 2017-03-07 Method for the absolute quantification of naturally processed hla-restricted cancer peptides
PH12017500483A PH12017500483A1 (en) 2014-12-30 2017-03-14 Method for the absolute qualification of naturally processed hla-restircted cancer peptides
CL2017001071A CL2017001071A1 (es) 2014-12-30 2017-04-28 Método para la cuantificación absoluta de péptidos cancerígenos hla-restringidos procesados naturalmente
CONC2017/0004543A CO2017004543A2 (es) 2014-12-30 2017-05-05 Método para la cuantificación absoluta de péptidos cancerosos restringidos a hla que son procesados de forma natural
US16/685,765 US11988669B2 (en) 2014-12-30 2019-11-15 Method for the absolute quantification of naturally processed hla-restricted cancer peptides
CY20211100514T CY1124223T1 (el) 2014-12-30 2021-06-10 Μεθοδος για τον ακριβη ποσοτικο προσδιορισμο των φυσικα επεξεργασμενων περιορισμενων me hla καρκινικων πεπτιδιων
US18/638,970 US20240280583A1 (en) 2014-12-30 2024-04-18 Method for the absolute quantification of naturally processed hla-restricted cancer peptides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1423361.3A GB201423361D0 (en) 2014-12-30 2014-12-30 Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides

Publications (1)

Publication Number Publication Date
GB201423361D0 true GB201423361D0 (en) 2015-02-11

Family

ID=52471641

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1423361.3A Ceased GB201423361D0 (en) 2014-12-30 2014-12-30 Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides

Country Status (35)

Country Link
US (3) US10545154B2 (enExample)
EP (1) EP3241026B1 (enExample)
JP (1) JP6735741B2 (enExample)
KR (1) KR102336968B1 (enExample)
CN (1) CN107003322B (enExample)
AU (1) AU2015373584B2 (enExample)
BR (1) BR112017008212B1 (enExample)
CA (1) CA2972306C (enExample)
CL (1) CL2017001071A1 (enExample)
CO (1) CO2017004543A2 (enExample)
CR (1) CR20170297A (enExample)
CY (1) CY1124223T1 (enExample)
DK (1) DK3241026T3 (enExample)
EA (1) EA036328B1 (enExample)
ES (1) ES2871035T3 (enExample)
GB (1) GB201423361D0 (enExample)
HR (1) HRP20210811T1 (enExample)
HU (1) HUE054455T2 (enExample)
IL (1) IL250982B (enExample)
LT (1) LT3241026T (enExample)
MA (2) MA41287B1 (enExample)
MD (1) MD3241026T2 (enExample)
MX (1) MX383806B (enExample)
MY (1) MY190199A (enExample)
PE (1) PE20171136A1 (enExample)
PH (1) PH12017500483A1 (enExample)
PL (1) PL3241026T3 (enExample)
PT (1) PT3241026T (enExample)
RS (1) RS61914B1 (enExample)
SG (2) SG11201703841VA (enExample)
SI (1) SI3241026T1 (enExample)
TW (1) TWI632370B (enExample)
UA (1) UA122774C2 (enExample)
WO (1) WO2016107740A1 (enExample)
ZA (1) ZA201701646B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201423361D0 (en) * 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
CR20210232A (es) * 2015-03-17 2022-06-24 Immatics Biotechnologies Gmbh NUEVOS PÉPTIDOS Y NUEVA COMBINACIÓN DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE PÁNCREAS Y OTROS TIPOS DE CÁNCER (Divisional 2017-0419)
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
MY198087A (en) 2015-10-05 2023-07-31 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
ES2871146T3 (es) 2017-07-14 2021-10-28 Immatics Biotechnologies Gmbh Molécula de polipéptido con especificidad dual mejorada
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
JP7470640B2 (ja) * 2018-02-09 2024-04-18 イマティクス ユーエス，アイエヌシー． Ｔ細胞を製造する方法
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
KR102731127B1 (ko) 2018-09-05 2024-11-18 에스케이하이닉스 주식회사 메모리 컨트롤러 및 이를 포함하는 메모리 시스템
TW202039535A (zh) 2018-12-18 2020-11-01 德商英麥提克生物技術股份有限公司 B*08限制肽和肽組合物抗癌免疫治療和相關方法
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
PH12021552979A1 (en) 2019-05-27 2023-10-09 Immatics Us Inc Viral vectors and their use in adoptive cellular therapy
US20200384028A1 (en) 2019-06-06 2020-12-10 Immatics Biotechnologies Gmbh Sorting with counter selection using sequence similar peptides
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
JP2022543687A (ja) 2019-08-09 2022-10-13 イマティクス ユーエス，アイエヌシー． ペプチド質量分析断片化を予測するための方法
US12480958B2 (en) 2019-08-13 2025-11-25 Immatics Biotechnologies Gmbh Method for the characterization of peptide:MHC binding polypeptides
MX2022010461A (es) 2020-02-24 2022-12-13 Immatics Us Inc Metodos para expandir linfocitos t para el tratamiento de cancer y neoplasias malignas asociadas.
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
JP2023527293A (ja) 2020-05-19 2023-06-28 アムジエン・インコーポレーテツド Ｍａｇｅｂ２結合構築物
US20220056411A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
DE102020125457A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
WO2022147029A2 (en) 2020-12-31 2022-07-07 Immatics US, Inc. Cd8 polypeptides, compositions, and methods of using thereof
US12162940B2 (en) 2021-05-05 2024-12-10 Immatics Biotechnologies Gmbh BMA031 antigen binding polypeptides
BR112023022765A2 (pt) 2021-05-05 2024-01-02 Immatics Biotechnologies Gmbh Proteínas de ligação ao antígeno que ligam especificamente o prame
EP4113120A1 (en) 2021-06-28 2023-01-04 Immatics Biotechnologies GmbH Method of characterizing the binding characteristics between a peptide of interest and mhc molecules
US20230024554A1 (en) 2021-06-28 2023-01-26 Immatics Biotechnologies Gmbh Method of characterizing the binding characteristics between a peptide of interest and mhc molecules
EP4377330A1 (en) 2021-07-27 2024-06-05 Immatics Biotechnologies GmbH Antigen binding proteins specifically binding ct45
WO2023025851A1 (en) 2021-08-24 2023-03-02 Immatics US, Inc. Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange
WO2023044488A1 (en) 2021-09-20 2023-03-23 Immatics US, Inc. Monocyte depletion of t cells populations for t-cell therapy
US20230190805A1 (en) 2021-10-06 2023-06-22 Immatics Biotechnologies Gmbh Methods of identifying metastatic lesions in a patient and treating thereof
EP4448108A1 (en) 2021-11-08 2024-10-23 Immatics Biotechnologies GmbH Adoptive cell therapy combination treatment and compositions thereof
JP2025516189A (ja) 2022-04-28 2025-05-27 イマティクス ユーエス，アイエヌシー． 膜結合型ｉｌ－１５、ｃｄ８ポリペプチド、細胞、組成物、およびそれらの使用方法
EP4514834A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
US20240066127A1 (en) 2022-04-28 2024-02-29 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
EP4519418A1 (en) 2022-05-05 2025-03-12 Immatics US, Inc. Methods for improving t cell efficacy
WO2025008513A1 (en) 2023-07-05 2025-01-09 Immatics Biotechnologies Gmbh A method of identifying mhc-binding proteins and interacting peptides in a sample
WO2025021979A1 (en) 2023-07-27 2025-01-30 Immatics Biotechnologies Gmbh Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same
TW202506719A (zh) 2023-07-27 2025-02-16 德商艾瑪提克生物技術有限公司 針對mageb2之抗原結合蛋白
WO2025040598A2 (en) 2023-08-18 2025-02-27 Immatics Biotechnologies Gmbh Peptides displayed by mhc for use in immunotherapy against different types of cancer
US20250134931A1 (en) 2023-11-01 2025-05-01 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2025125535A1 (en) 2023-12-13 2025-06-19 Immatics Biotechnologies Gmbh Differential population-scale immunopeptidomics
WO2025125536A1 (en) 2023-12-13 2025-06-19 Immatics Biotechnologies Gmbh Absolute copy number prediction of mhc-presented peptides by relative quantitative measurement
WO2025233420A1 (en) 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Use of anti-cancer molecules
WO2025233431A1 (en) 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1425586T3 (da) 2001-09-14 2008-02-11 Electrophoretics Ltd Massemarkörer
DE10225139A1 (de) 2002-05-29 2004-02-26 Immatics Biotechnologies Gmbh Verfahren zur Identifizierung von immunreaktiven Peptiden
US20050221350A1 (en) * 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
US6644103B1 (en) 2002-10-24 2003-11-11 Simmonds Precision Products, Inc. Method and apparatus for detecting a dry/wet state of a thermistor bead
EP1566639A4 (en) * 2002-11-08 2006-10-11 Hiroshi Takahashi METHOD FOR EXAMINING CANCER CELLS AND REAGENT THEREOF
US7811828B2 (en) 2004-01-28 2010-10-12 Immatics Biotechnologies Gmbh Method for identifying and quantifying of tumuor-associated
JP2008043332A (ja) * 2006-08-17 2008-02-28 Panomics Inc 組織スライドからの核酸定量
DK2172211T3 (en) * 2008-10-01 2015-02-16 Immatics Biotechnologies Gmbh Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201006360D0 (en) * 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
US20140051092A1 (en) 2011-04-15 2014-02-20 Micromass Uk Limited Method And Apparatus For The Analysis Of Biological Samples
WO2012178030A2 (en) 2011-06-24 2012-12-27 Applied Isotope Technologies, Inc. Accurate measurement of glutathione for disease diagnosis and drug metabolite screening
US10077171B2 (en) * 2012-10-17 2018-09-18 Grant C. Chustz Safety barrier for vehicles and cranes
GB201423361D0 (en) * 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
DE102016115246C5 (de) * 2016-08-17 2018-12-20 Immatics Biotechnologies Gmbh Neue t-zellrezeptoren und deren verwendung in immuntherapie
IL308007A (en) * 2017-11-06 2023-12-01 Immatics Biotechnologies Gmbh Transgenic T-cell receptors and immunotherapy using them

Also Published As

Publication number Publication date
CN107003322A (zh) 2017-08-01
MY190199A (en) 2022-04-04
ES2871035T3 (es) 2021-10-28
EA036328B1 (ru) 2020-10-27
US20240280583A1 (en) 2024-08-22
MA41287A (fr) 2017-11-08
KR102336968B1 (ko) 2021-12-08
PT3241026T (pt) 2021-05-25
AU2015373584A1 (en) 2017-04-20
TW201631320A (zh) 2016-09-01
EP3241026B1 (en) 2021-04-14
WO2016107740A1 (en) 2016-07-07
MD3241026T2 (ro) 2021-07-31
MA40137A1 (fr) 2018-03-30
US11988669B2 (en) 2024-05-21
BR112017008212A2 (pt) 2017-12-26
PE20171136A1 (es) 2017-08-09
US20160187351A1 (en) 2016-06-30
CA2972306C (en) 2021-02-16
LT3241026T (lt) 2021-05-25
CO2017004543A2 (es) 2017-09-29
RS61914B1 (sr) 2021-06-30
CR20170297A (es) 2017-10-19
CA2972306A1 (en) 2016-07-07
HRP20210811T1 (hr) 2021-09-03
PH12017500483A1 (en) 2017-08-07
KR20170099914A (ko) 2017-09-01
AU2015373584B2 (en) 2022-02-24
EA201791148A1 (ru) 2017-11-30
IL250982B (en) 2020-08-31
SG11201703841VA (en) 2017-07-28
SI3241026T1 (sl) 2021-08-31
MX2017008722A (es) 2017-10-18
HUE054455T2 (hu) 2021-09-28
EP3241026A1 (en) 2017-11-08
MA40137B1 (fr) 2019-05-31
TWI632370B (zh) 2018-08-11
US10545154B2 (en) 2020-01-28
JP2018500004A (ja) 2018-01-11
JP6735741B2 (ja) 2020-08-05
SG10201913988XA (en) 2020-03-30
PL3241026T3 (pl) 2021-10-25
CY1124223T1 (el) 2022-05-27
US20200103408A1 (en) 2020-04-02
CL2017001071A1 (es) 2017-12-22
MX383806B (es) 2025-03-14
CN107003322B (zh) 2019-08-30
DK3241026T3 (da) 2021-05-10
ZA201701646B (en) 2018-05-30
BR112017008212B1 (pt) 2023-11-28
MA41287B1 (fr) 2021-07-29
UA122774C2 (uk) 2021-01-06
IL250982A0 (en) 2017-04-30

Similar Documents

Publication Publication Date Title
ZA201701646B (en) Method for the absolute quantification of naturally processed hla-restricted cancer peptides
PT3368683T (pt) Método para a quantificação de pd-l1
GB2547966B (en) De-aliased source separation method
GB201612214D0 (en) Method
HUP1400114A2 (en) Method for the production of peptides
GB2547965B (en) Source separation method
IL248283B (en) A method for the synthesis of cloprabine
GB201603367D0 (en) Method
IL259107B (en) A method to remove camouflage from an object
GB201506117D0 (en) Method for chromatography
GB201506113D0 (en) Method for chromatography
IL257514A (en) A method for detecting cancer
IL247270B (en) A method for detecting cancer
IL258898A (en) Methods for the synthesis of 2-alkyl-4-trifluoromethyl-3-alkylsulfonylbenzoic acids
PL3336368T3 (pl) Sposób bezobrotowego łączenia dwóch elementów
GB201601120D0 (en) Eye-testing method
GB201604809D0 (en) Method for detecting cancer
GB201607828D0 (en) Method
GB201607463D0 (en) Method
GB201522150D0 (en) Saftey Apparatus
SG11201707200PA (en) Method for shape classification of an object
GB201602413D0 (en) Method
GB201601040D0 (en) Method
GB201600721D0 (en) Method
GB201518261D0 (en) Method of forming an object

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)